← board
PVCT
distress 5/10 · elevated risk$0.06-5%today-42% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.1 yrs
Shares 1y
0%
Price & events
-6.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-5.0%
1D
-12.5%
1W
-19.0%
1M
+4.0%
3M
-5.0%
6M
-24.5%
1Y
-52.1%
2Y
-19.0%
5Y
+0.2%
All
Overview
- Market Cap
- $23.16M
- Volume
- 26.50K
- 52 Week Range
- $0.04 – $0.10
- Total Shares
- 420.28M
- Float Shares
- 387.95M
- Short %
- 0.78%
- % Held by Insiders
- 7.48%
- % Held by Institutions
- 0.05%
- RVOL
- 0.15x
- Beta
- 0.83
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- June 18, 2026conferencedata presentationsecondaryAnnual Meeting of StockholdersSEC 8-K
- 2024-12-05partnershiprose bengal sodium · Formed subsidiary VisiRose with University of Miami to commercialize RB PDAT for infectious keratitisSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- 2026-07-22Form 13D/A PROVECTUS BIOPHARMACEUTICALS For: 22 July By Investing.com - Investing.com Canada
- 2026-07-22Provectus Biopharmaceuticals (PVCT) CEO holds 52.4M shares, 11.61% stake - Stock Titan
- 2026-07-22VisiRose Selected to Present RB-PDAT at ESCRS iNovation® Day 2026 Emerging Company Showcase - GlobeNewswire
- 2026-07-07Independent University of Lille Study Shows Rose Bengal - GlobeNewswire
- 2026-07-07French melanoma study finds the same dose of Provectus RBS can boost and suppress immunity - Stock Titan
- 2026-07-07Independent University of Lille Study Shows Rose Bengal - GlobeNewswire
- 2026-07-02Provectus Biopharmaceuticals Inc (OTC: PVCT) Share Price, PVCT Stock News, PVCT Share Price & Updates - Kalkine
- 2026-07-02Provectus (NASDAQ: PVCT) CEO updates Form 4 to correct Series D-1 preferred holdings - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.